European urology最新文献

{"title":"Platinum Hall of Fame","authors":"","doi":"10.1016/j.eururo.2025.02.008","DOIUrl":"10.1016/j.eururo.2025.02.008","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 4","pages":"Pages e59-e69"},"PeriodicalIF":25.3,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143653573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Congress Calendar","authors":"","doi":"10.1016/j.eururo.2025.02.009","DOIUrl":"10.1016/j.eururo.2025.02.009","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 4","pages":"Pages e75-e76"},"PeriodicalIF":25.3,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143653574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genitourinary Pathology Society and International Society of Urological Pathology White Paper on Defining Indolent Prostate Cancer: Call for a Multidisciplinary Approach","authors":"Rajal B. Shah, Gladell P. Paner, Liang Cheng, Angelo M. De Marzo, Cristina Magi-Galluzzi, Murali Varma, Ming Zhou, Ali Amin, Mahul B. Amin, Manju Aron, Isabela W. Cunha, Jonathan I. Epstein, Samson W. Fine, Aiman Haider, Kenneth A. Iczkowski, James G. Kench, Lakshmi Priya Kunju, Sambit K. Mohanty, Rodolfo Montironi, George J. Netto, Glen Kristiansen","doi":"10.1016/j.eururo.2025.02.029","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.02.029","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>How to detect indolent PC</h2>Indolent PC can only be detected in prostate tissue that is entirely resected at radical prostatectomy (RP).<ul><li><span></span><span><strong><em>Outcomes for GG 1 PC detected in totally examined RP specimens are excellent.</em></strong></span></li></ul>Among cases for which RP specimens harbor pure GG 1 PC, metastasis to lymph nodes and distant sites and PC-specific mortality (PCSM) do not occur. Extraprostatic extension is uncommon (up to 6%) and seminal vesicle invasion is rare (0.03%).<ul><li><span></span><span><strong><em>Most incidentally detected PCs in cystoprostatectomy specimens are GG 1</em></strong></span></li></ul></section></section><section><section><h2>Can indolent PC be reliably detected at biopsy?</h2>A diagnosis of GG 1 PC diagnosis on needle biopsy (NBx) is not always identical to a diagnosis of GG 1 PC at RP. Reliable identification of indolent PC at NBx is not possible.<ul><li><span></span><span><strong><em>A subset of GG 1 PCs at NBx are upgraded to a higher grade at RP.</em></strong></span></li></ul>Despite the combination of magnetic resonance imaging (MRI)-targeted and systematic biopsies, substantial upgrading at RP still occurs in 22–27% of biopsy GG 1 PC cases because of sampling error or potential progression [3,4].<ul><li><span></span><span><strong><em>GG 1 PC reclassification during</em></strong></span></li></ul></section></section><section><section><h2>How can we improve our ability to correctly classify indolent PC at NBx?</h2>The optimal definition of indolent PC at NBx can be improved via contemporary multidisciplinary approaches.<ul><li><span></span><span><strong><em>A contemporary “histopathological definition” that captures (does not define) the majority of indolent PCs would include GG 1, no equivocal GP 3/GP 4, no cribriform PC (cribriform GP 4/intraductal carcinoma), and no stromal desmoplasia (“stromogenic” PC).</em></strong></span></li></ul>This histopathological definition must be combined with other multidisciplinary factors for optimal identification of indolent PC.<ul><li><span></span><span><strong><em></em></strong></span></li></ul></section></section>","PeriodicalId":12223,"journal":{"name":"European urology","volume":"59 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143640661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Alexandra Masson-Lecomte. Bladder Cancer Recurrence Following Management of Upper Tract Urothelial Carcinoma: Balancing Prevention and Iatrogenicity. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.01.004","authors":"Thomas van Doeveren, Katja K.H. Aben, Pim J. van Leeuwen, Joost L. Boormans","doi":"10.1016/j.eururo.2025.02.028","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.02.028","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"12 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143640656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Updated Systematic Review and Meta-analysis of Extracorporeal Shock Wave Lithotripsy, Flexible Ureterorenoscopy, and Percutaneous Nephrolithotomy for Lower Pole Renal Stones","authors":"Steven MacLennan, Oliver Wiseman, Daron Smith, Kathryn Starr, Lorna Aucott, Rodolfo Hernández, Paul Manson, Ruth Thomas, Charles Terry Clark, Graeme MacLennan, Dawn McRae, Victoria Bell, Seonaidh Cotton, Zara Gall, Ben Turney, Sam McClinton","doi":"10.1016/j.eururo.2025.01.020","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.01.020","url":null,"abstract":"Lower pole stones (LPSs) frequently cause significant morbidity, necessitating effective intervention strategies. We systematically reviewed the evidence for treatment of LPSs with extracorporeal shock wave lithotripsy (ESWL), flexible ureterorenoscopy (FURS), and percutaneous nephrolithotomy (PCNL) previously in 2015. In this update, we have included 16 new randomised controlled trials plus eight from our original review (24 in total). Despite the increase in available trials, the certainty of evidence remains moderate for stone-free rates (SFRs), underscoring the on-going need for more robust trials in this domain. FURS demonstrated superior efficacy in achieving SFRs to ESWL (risk ratio [RR] 1.19, 95% confidence interval [CI] 1.05, 1.35), although the absolute difference remains modest. ESWL may lead to fewer complications, and FURS could result in more unplanned procedures and retreatments. It remains unclear whether there are differences in quality of life and cost estimates vary depending on the country. PCNL offers a marginal yet statistically significant advantage over FURS in terms of SFRs (RR 1.07, 95% CI 1.01, 1.12), but it is unclear whether there are differences in unplanned procedures, retreatments, or complications, and there was conflicting evidence about health status and return to normal activities. SFRs were superior with PCNL to those with ESWL (RR 1.42 95% CI 1.28, 1.58). Unplanned procedures and retreatments were generally fewer for PCNL, and complications were fewer for ESWL. The cost effectiveness of each modality is highly dependent on the health care system and country-specific economic factors. The overall certainty of the evidence remains unchanged, with only moderate improvements in certain domains.","PeriodicalId":12223,"journal":{"name":"European urology","volume":"68 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143608376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Tranexamic Acid During Radical Cystectomy: A Randomized Clinical Trial","authors":"Paolo Zaurito, Marco Moschini, Giorgio Gandaglia, Alberto Briganti, Francesco Montorsi","doi":"10.1016/j.eururo.2025.02.013","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.02.013","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"9 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143599492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"T-cell Engagers in Prostate Cancer","authors":"Chadi Hage Chehade ,&nbsp;Zeynep Irem Ozay ,&nbsp;Micah Ostrowski ,&nbsp;Chiara Mercinelli ,&nbsp;Georges Gebrael ,&nbsp;Nicolas Sayegh ,&nbsp;Umang Swami ,&nbsp;Arun A. Azad ,&nbsp;Emmanuel S. Antonarakis ,&nbsp;Neeraj Agarwal","doi":"10.1016/j.eururo.2025.02.001","DOIUrl":"10.1016/j.eururo.2025.02.001","url":null,"abstract":"<div><div>Owing to the “cold” tumor immune microenvironment of prostate cancer, immune-targeting agents have shown limited efficacy in patients with advanced prostate cancer, highlighting the need for new therapies with novel mechanisms of action. In this context, T-cell engagers (TCEs), which induce T-cell–mediated killing of cancer cells by binding the CD3 receptor on T cells and a specific tumor antigen expressed on malignant cells, represent a promising therapeutic option. Multiple studies have explored the use of TCEs in previously treated patients with metastatic castration-resistant prostate cancer, and several ongoing trials are currently assessing novel TCEs either as single agents or in combinatorial regimens with molecules with a distinct mechanism of action (eg, androgen receptor pathway inhibitors and other immune-targeting agents). Although TCEs have shown promising antitumor activity with prostate-specific antigen and radiographic responses, they still face considerable challenges that prevent their implementation into clinical practice. These include their immunogenicity and the development of antidrug antibodies, which could impact their serum drug exposure, as well as their toxicity profile involving cytokine release syndrome and other immune-related adverse events. To improve their efficacy and pending the results of ongoing trials, there could be a role for combinatorial regimens, administration in earlier lines of therapy, and biomarker-driven selection.</div></div>","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 5","pages":"Pages 553-558"},"PeriodicalIF":25.3,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143599609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Paolo Gontero, Alison Birtle, Otakar Capoun, et al. European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)—A Summary of the 2024 Guidelines Update. Eur Urol 2024;86:531–49","authors":"Francesco Montorsi,&nbsp;Giuseppe Rosiello,&nbsp;Giorgio Gandaglia,&nbsp;Andrea Salonia,&nbsp;Alberto Briganti","doi":"10.1016/j.eururo.2025.01.030","DOIUrl":"10.1016/j.eururo.2025.01.030","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 5","pages":"Page e93"},"PeriodicalIF":25.3,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143599493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Francesco Montorsi, Giuseppe Rosiello, Giorgio Gandaglia, Andrea Salonia and Alberto Briganti’s Letter to the Editor re: Paolo Gontero, Alison Birtle, Otakar Capoun, et al. European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)—A Summary of the 2024 Guidelines Update. Eur Urol 2024;86:531–49","authors":"Paolo Gontero,&nbsp;Francesco Soria,&nbsp;European Association of Urology NMIBC Guidelines Panel","doi":"10.1016/j.eururo.2025.02.021","DOIUrl":"10.1016/j.eururo.2025.02.021","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 5","pages":"Pages e94-e95"},"PeriodicalIF":25.3,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143599495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"When Less Is More: The Challenges of Defining Residual Disease Following Neoadjuvant Hormonal Therapy in Prostate Cancer","authors":"Gaëtan Devos, Alexander Giesen, Steven Joniau","doi":"10.1016/j.eururo.2025.02.025","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.02.025","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"86 2 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143589994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}